Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Committee approves AB 1103 to speed state review of federally approved controlled‑substance clinical research
Summary
AB 1103 would create an expedited state review process for federally sanctioned clinical research involving Schedule I and II controlled substances by updating the Research Advisory Panel of California (RAP C) procedures. Sponsors said the change would prevent long delays that have halted studies; witnesses included veterans who sought treatment.
Assembly Bill 1103: The Senate Committee on Health considered AB 1103, which would create an expedited state review and approval pathway for federally authorized drug trials and clinical research involving Schedule I and II controlled substances through the Research Advisory Panel of California (RAP C), housed in the Department of Justice.
Why it matters: Supporters said the current RAP C process can delay research start dates—sometimes halting studies for months—because panel…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
